Efficacy endpoints in oncology

Efficacy endpoints in Oncology - Lex Jansen

PhUSE 2013 1 Paper IS01 Efficacy endpoints in Oncology Angelo Tinazzi, Cytel Inc., Geneva, Switzerland ABSTRACT The evaluation of efficacy in oncology studies, in particular for solid tumors, is pretty standard and well defined by several

  Oncology, Efficacy, Endpoint, Efficacy endpoints in oncology, Efficacy in oncology

000079-OGYT-Protocol-LATE-PHASE ONCOLOGY …

Redacted PARAMOUNT Clinical Protocol Page 1 Pemetrexed Redacted Protocol for Journal of Clinical Oncology . Protocol S124(b) (PARAMOUNT) A Phase 3, Double-Blind, Placebo-Controlled Study of

  Protocol, Oncology

The Investigational New Drug (IND) and New Drug ...

The Investigational New Drug (IND) and New Drug Application (NDA) Process Susan Honig, MD Division of Oncology Drug Products. US Food & Drug Administration

  Drug, Oncology, Investigational, The investigational new drug

Guidance for Industry - Food and Drug …

Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics U.S. Department of Health and Human Services Food and Drug Administration

  Administration, Drug, Guidance, Food and drug administration, Food, Food and drug, Industry, Guidance for industry, Endpoint

Assessment report - European Medicines Agency

Zaltrap CHMP assessment report Page 2/91 Executive Summary Colorectal cancer (CRC) is one of the most common cancer s in both men and women, and the second

  Assessment, Report, Assessment report

Guideline on the evaluation of anticancer medicinal ...

This guideline replaces guideline on the evaluation of anticancer medicinal products in man' EMA/CHMP/205/95 Rev 4

  Product, Evaluation, Medicinal, Anticancer, The evaluation of anticancer medicinal, The evaluation of anticancer medicinal products

Advanced Therapy Medicinal Products (ATMPs)

An agency of the European Union Presented by: B. Brake and A. Ganan Jimenez European Medicines Agency Advanced Therapy Medicinal Products (ATMPs)

  Product, Advanced, Therapy, Medicinal, Advanced therapy medicinal products, Atmps

LIBRETTO-001: A phase 1 study of LOXO-292, a …

LIBRETTO-001: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers Alexander Drilon,1 Vivek Subbiah,2 Geoffrey R. Oxnard,3 Todd M. Bauer,4 Vamsidhar Velcheti,5 Nehal J. Lakhani,6